Pertinent to this review, RAS/MAPK pathway was demonstrated to regulate FOXC1 expression in breast cancer (68), suggesting that targeted inhibition of this pathway may offer therapeutic benefit in FOXC1+ pro-metastatic cancers (Figure 3). This evidence concerns the gene FOXC1 and breast carcinoma.